July 19, 2019 — Medical device startup company Filterlex Medical recently completed a series A financing round, raising a total of $3 million for its Captis embolic protection device for reducing the risk of stroke and other complications during catheter-based structural heart procedures. Captis won Best Innovation Award at the EuroPCR 2019 innovation competition in Paris and was awarded a grant of $200,000 by the Jon DeHaan foundation.
During catheter-based, left-heart procedures such as transcatheter aortic valve implantation (TAVI), embolic particles are often released to the blood flow. Particles migration to the brain may cause a spectrum of neurological deficiencies, from cognitive impairment to debilitating stroke. Emboli released to distal organs may result in acute kidney injury and ischemia. The Captis device is a next-generation full-body embolic protection device, easily and intuitively deployed and retrieved. The device is securely positioned in the aorta and protects its surface while facilitating a seamless TAVI procedure. Its triple-action design provides a full-body embolic protection by deflecting, capturing and removing embolic particles. It requires no additional arterial access and does not interfere with the procedure workflow.
For more information: www.filterlex.com
April 07, 2026 
